MedTrace Logo

Pregabalin for the Prevention of Chemotherapy Induced Nausea and Vomiting

NCT04181346 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2019-11-29

No results posted yet for this study

Summary

phase II randomized, double-blind, placebo-controlled trial to investigate whether pregabalin can improve the complete control of nausea and vomiting (primary end point)

Conditions

Interventions

DRUG

Pregabalin

antipsychotic

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Faculdade de Medicina do ABC

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-01
Primary Completion
2020-02-28
Completion
2020-02-28

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04181346 on ClinicalTrials.gov